Anupam Rasayan India Limited — PPTs, 13-02-2025: Investor Presentation

**Financial Highlights:** Anupam Rasayan India Ltd. reported a consolidated total revenue of ₹3,866 Mn for Q3FY25, reflecting a robust 31% quarter-over-quarter growth. Standalone revenue reached ₹2,092 Mn with an 8% quarter-over-quarter increase. Standalone EBITDA stood at ₹693 Mn with a margin of 33%, while PAT grew to ₹191 Mn, marking a 37% quarter-over-quarter increase. Consolidated EBITDA was reported at ₹1,208 Mn with a margin of 31%, and consolidated PAT surged to ₹542 Mn, up by 77%.

**Strategic Initiatives and Growth Drivers:** The company is expanding its pharmaceutical and polymer segments, which are becoming key growth drivers. The addition of two new products this quarter brought the total to 75. Anupam Rasayan anticipates a continued upward trend, projecting a 30-35% revenue increase in FY26.

**Business Developments:** The company has signed significant contracts and LOIs collectively valued at ₹8,919 crore, which includes commercialized products and several anticipated launches stretching into FY26.

**Market Position and Competitive Advantage:** Anupam boasts a strong manufacturing capacity of over 30,000 MT across six facilities, enhancing its ability to meet global demand. Its technical capabilities in complex chemistries position it favorably against competitors.

**Investor Implications:** With strong growth in revenues driven by key segments and a solid order book, investors may view this as a positive outlook for the company heading into FY26. Watch closely for how the execution of contracts and new product commercialization unfold.